Growth Hormone Secretagogue Receptor Type 1 - Pipeline Review, H2 2019 - ResearchAndMarkets.com

DUBLIN--()--The "Growth Hormone Secretagogue Receptor Type 1 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Summary

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Growth hormone secretagogue receptor (GHSR) also known as ghrelin receptor, is a G protein-coupled receptor that binds ghrelin. Ghrelin is an appetite-regulating factor secreted from peripheral organs via binding to the receptor resulting in the secretion of growth hormone by the pituitary gland. The pathway activated by binding of ghrelin to the growth hormone secretagogue receptor, GHSR1a, regulates the activation of the downstream mitogen-activated protein kinase, Akt, nitric oxide synthase, and AMPK cascades in different cellular systems. Inverse agonists for the ghrelin receptor could be particularly interesting for the treatment of obesity.

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) pipeline Target constitutes close to 19 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 2, 10 and 1 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively.

The latest report Growth Hormone Secretagogue Receptor Type 1 - Pipeline Review, H2 2019, outlays comprehensive information on the Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)
  • The report reviews Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Key Topics Covered:

  • Introduction
  • Report Coverage
  • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Overview
  • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Companies Involved in Therapeutics Development
  • Aeterna Zentaris Inc
  • Allergan Plc
  • AstraZeneca Plc
  • Daiichi Sankyo Co Ltd
  • Extend Biosciences Inc
  • Helsinn Group
  • Lumos Pharma Inc
  • Millendo Therapeutics Inc
  • Oxeia Biopharmaceuticals Inc
  • Pfizer Inc
  • RaQualia Pharma Inc
  • TheraSource LLC
  • Zeria Pharmaceutical Co Ltd
  • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Drug Profiles
  • anamorelin hydrochloride - Drug Profile
  • AZ-12861903 - Drug Profile
  • EXT-405 - Drug Profile
  • EXT-418 - Drug Profile
  • HM-03 - Drug Profile
  • HM-04 - Drug Profile
  • ibutamoren mesylate - Drug Profile
  • livoletide - Drug Profile
  • macimorelin acetate - Drug Profile
  • OXE-103 - Drug Profile
  • Peptide to Agonize GHSR for Acute Ischemic Stroke, Acute Radiation Syndrome and Sepsis - Drug Profile
  • PF-05190457 - Drug Profile
  • relamorelin - Drug Profile
  • RQ-00433412 - Drug Profile
  • Small Molecule to Antagonize Ghrelin Receptor for Obesity - Drug Profile
  • Small Molecule to Antagonize Ghrelin Receptor for Obesity - Drug Profile
  • Small Molecules to Agonize GHSR for Cachexia - Drug Profile
  • Synthetic Peptide to Modulate GHSR for Chronic Kidney Disease - Drug Profile
  • Z-505 - Drug Profile
  • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Dormant Products
  • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Discontinued Products
  • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Product Development Milestones
  • Featured News & Press Releases

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/do2yrw

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900